Thyroid Dysfunction after Atezolizumab and Bevacizumab Is Associated with Favorable Outcomes in Hepatocellular Carcinoma

Introduction: Atezolizumab and bevacizumab (Ate/Bev) combination has become the new first-line systemic therapy for unresectable hepatocellular carcinoma (HCC). Although several studies reported thyroid dysfunction after treatment with immune checkpoint inhibitors, the clinical and immunological sig...

وصف كامل

التفاصيل البيبلوغرافية

المؤلفون الرئيسيون:	Young Shin Song, Hannah Yang, Beodeul Kang, Jaekyung Cheon, Ilhwan Kim, Hyeyeong Kim, Won Suk Lee, Yun Beom Sang, Sanghoon Jung, Ho Yeong Lim, Vincent E. Gaillard, Chan Kim, Hong Jae Chon
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	Karger Publishers 2023-05-01
سلاسل:	Liver Cancer
الموضوعات:	hepatocellular carcinoma thyroid adverse events atezolizumab bevacizumab
الوصول للمادة أونلاين:	https://beta.karger.com/Article/FullText/531182
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!